Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402233 | 0.83 | KCNQ4 (0.43) | KCNQ4KCNQ5 | |
| SCHEMBL6402953 | 0.73 | ABCC1 (0.53) | KCNQ4KCNQ5NPC1RAB9ACA2 | |
| SCHEMBL28740739 | 0.71 | ELANE (0.41) | CA1MAPT | |
| SCHEMBL3986782 | 0.70 | METAP2 (0.47) | KCNQ4KCNQ5SMN1; SMN2CA1 | |
| SCHEMBL6402812 | 0.70 | ELANE (0.56) | KCNQ4KCNQ5CTSK | |
| SCHEMBL28210980 | 0.70 | BRD9 (0.39) | CA1MAPT | |
| SCHEMBL3988441 | 0.69 | BRD9 (0.38) | NPC1RAB9ASMN1; SMN2CA1MAPT | |
| SCHEMBL6395566 | 0.69 | CISD2 (0.40) | NPC1RAB9ACA1MAPT | |
| SCHEMBL4489061 | 0.66 | KCNQ4 (0.38) | KCNQ4KCNQ5MAPT | |
| SCHEMBL379892 | 0.66 | CA2 (0.54) | NPC1RAB9ASMN1; SMN2NAMPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6806269-B1 | EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE | G. D. SEARLE & COP | 2004-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | CNR1 1968/4885KCNQ4 264/4885KCNQ5 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.